Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05RII
|
|||
Former ID |
DNC006738
|
|||
Drug Name |
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
|
|||
Synonyms |
CHEMBL210770; 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole; SCHEMBL14280723; NRIVFQIOYWIUPX-UHFFFAOYSA-N; BDBM50185792
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C20H21ClN2
|
|||
Canonical SMILES |
C1CN(CCC1C2=CNC3=C2C=C(C=C3)Cl)CC4=CC=CC=C4
|
|||
InChI |
1S/C20H21ClN2/c21-17-6-7-20-18(12-17)19(13-22-20)16-8-10-23(11-9-16)14-15-4-2-1-3-5-15/h1-7,12-13,16,22H,8-11,14H2
|
|||
InChIKey |
NRIVFQIOYWIUPX-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [1] | |
Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Estrogen signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Opioid prodynorphin pathway | ||||
Enkephalin release | ||||
Pathway Interaction Database | IL4-mediated signaling events | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
TCR Signaling Pathway | ||||
Opioid Signalling |
References | Top | |||
---|---|---|---|---|
REF 1 | 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.